Preliminary results from the EMoLung clinical study showing early lung cancer detection by the LC score

Abstract

Background Lung cancer (LC) causes more deaths worldwide than any other cancer type. Despite advances in therapeutic strategies, the fatality rate of LC cases remains high (95%) since the majority of patients are diagnosed at late stages when patient prognosis is poor. Analysis of the International Association for the Study of Lung Cancer (IASLC) database indicates that early diagnosis is significantly associated with favorable outcome. However, since symptoms of LC at early stages are unspecific and resemble those of benign pathologies, current diagnostic approaches are mostly initiated at advanced LC stages. Methods We developed a LC diagnosis test based on the analysis of distinct RNA isoforms expressed from the GATA6 and NKX2-1 gene loci, which are detected in exhaled breath condensates (EBCs). Levels of these transcript isoforms in EBCs were combined to calculate a diagnostic score (the LC score). In the present study, we aimed to confirm the applicability of the LC score for the diagnosis of early stage LC under clinical settings. Thus, we evaluated EBCs from patients with early stage, resectable non-small cell lung cancer (NSCLC), who were prospectively enrolled in the EMoLung study at three sites in Germany. Results LC score-based classification of EBCs confirmed its performance under clinical conditions, achieving a sensitivity of 95.7%, 91.3% and 84.6% for LC detection at stages I, II and III, respectively. Conclusions The LC score is an accurate and non-invasive option for early LC diagnosis and a valuable complement to LC screening procedures based on computed tomography.

ncRNAs Orchestrate Chemosensitivity Induction by Neddylation Blockades

“…Lung cancer is usually detected only at a late stage as most patients have no obvious symptoms at the early stages of the disease [1][2][3]. Consequently, early implementation of screening programs has been proposed as one of the main tools for patients to reduce lung cancer-associated mortality [4][5][6]. Nevertheless, lung cancer has one of the lowest long-term survival rates and most lung cancers are metastatic at diagnosis, which in turn contributes to patients' low overall survival rates [7][8][9].…”